Biblio

Author Title [ Type

] Year

Filters: Author is Jurczyszyn, Artur [Clear All Filters]

Journal Article

Gołos A, Gil L, Puła B, Boguradzki P, Hałaburda K, Sawicki W, Sobczyk-Kruszelnicka M, Helbig G, Dybko J, Jurczyszyn A, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group. Adv Med Sci. 2020;65(2):429-436.

Batko K, Malyszko J, Jurczyszyn A, Vesole DH, Gertz MA, Leleu X, Suska A, Krzanowski M, Sulowicz W, Malyszko JS, et al. The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and monoclonal gammopathy of renal significance. Nephrol Dial Transplant. 2018.

Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, P Ho J, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2023.

Jurczyszyn A, Kosmaczewska A, Skotnicki AB. Daratumumab - breakthrough drug in multiple myeloma therapy. Postepy Hig Med Dosw (Online). 2014;68:1352-1360.

Pour L, Szarejko M, Bila J, Schjesvold FH, Spicka I, Maisnar V, Jurczyszyn A, Grudeva-Popova Z, Hajek R, Usenko G, et al. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study. Haematologica. 2023.

Waszczuk-Gajda A, Małyszko J, Vesole DH, Feliksbrot-Bratosiewicz M, Skwierawska K, Krzanowska K, Kobylińska K, Biecek P, Snarski E, Rodziewicz-Lurzyńska A, et al. Negative Impact of Borderline Creatinine Concentration and Glomerular Filtration Rate at Baseline on the Outcome of Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplant. Transplant Proc. 2020.

Avivi I, Vesole DH, Dávila-Valls J, Usnarska-Zubkiewicz L, Olszewska-Szopa M, Milunovic V, Baumert B, Osękowska B, Kopińska A, Gentile M, et al. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients. Cancers (Basel). 2023;15(17).

Długosz-Danecka M, Hus I, Puła B, Jurczyszyn A, Chojnacki T, Blajer-Olszewska B, Drozd-Sokołowska J, Raźny M, Romejko-Jarosińska J, Taszner M, et al. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis. Pharmacol Rep. 2019;71(3):473-477.

Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Dávila J, Vij R, Fiala MA, Gozzetti A, Grzasko N, Milunovic V, et al. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma. 2018:1-6.

Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e105-e118.